AU2013250801A1 - Process for the preparation of rivaroxaban and intermediates thereof - Google Patents

Process for the preparation of rivaroxaban and intermediates thereof Download PDF

Info

Publication number
AU2013250801A1
AU2013250801A1 AU2013250801A AU2013250801A AU2013250801A1 AU 2013250801 A1 AU2013250801 A1 AU 2013250801A1 AU 2013250801 A AU2013250801 A AU 2013250801A AU 2013250801 A AU2013250801 A AU 2013250801A AU 2013250801 A1 AU2013250801 A1 AU 2013250801A1
Authority
AU
Australia
Prior art keywords
formula
compound
rivaroxaban
preparation
iii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2013250801A
Other languages
English (en)
Inventor
Mohammed Salman Hashmi
Chandra Has Khanduri
Yoginder Pal Sachdeva
Pankaj Kumar Singh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharmaceutical Industries Ltd
Original Assignee
Ranbaxy Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Laboratories Ltd filed Critical Ranbaxy Laboratories Ltd
Publication of AU2013250801A1 publication Critical patent/AU2013250801A1/en
Assigned to SUN PHARMACEUTICAL INDUSTRIES LIMITED reassignment SUN PHARMACEUTICAL INDUSTRIES LIMITED Amend patent request/document other than specification (104) Assignors: RANBAXY LABORATORIES LIMITED
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2013250801A 2012-04-16 2013-04-16 Process for the preparation of rivaroxaban and intermediates thereof Abandoned AU2013250801A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1174/DEL/2012 2012-04-16
IN1174DE2012 2012-04-16
PCT/IB2013/053025 WO2013156936A1 (en) 2012-04-16 2013-04-16 Process for the preparation of rivaroxaban and intermediates thereof

Publications (1)

Publication Number Publication Date
AU2013250801A1 true AU2013250801A1 (en) 2014-11-06

Family

ID=48539327

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013250801A Abandoned AU2013250801A1 (en) 2012-04-16 2013-04-16 Process for the preparation of rivaroxaban and intermediates thereof

Country Status (6)

Country Link
US (1) US20150299160A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2838897A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2013250801A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2014DN09450A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG11201406623PA (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2013156936A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103819468A (zh) * 2013-12-05 2014-05-28 浙江天宇药业股份有限公司 一种利伐沙班及其中间体的合成方法
WO2015104605A1 (en) 2014-01-08 2015-07-16 Wockhardt Limited A process for preparing rivaroxaban or a pharmaceutically acceptable salt thereof
CN104478820B (zh) * 2014-12-22 2016-08-31 杭州瀚康生物医药科技有限公司 一种利伐沙班中间体的制备方法
CN104910141B (zh) * 2015-05-12 2018-11-02 浙江天顺生物科技有限公司 一种利伐沙班中间体5-氯-n-(2-环氧乙烷基甲基)-2-噻吩甲酰胺的制备方法
CN104788444B (zh) * 2015-05-12 2018-11-06 浙江天顺生物科技有限公司 利伐沙班的制备方法
CN104817550B (zh) * 2015-05-26 2017-06-16 山东铂源药业有限公司 一种利伐沙班的制备方法
CN108707080B (zh) * 2018-06-20 2022-01-25 上海圣赢生物科技有限公司 一种利奈唑胺及其中间体的环保合成方法
CN109400577B (zh) * 2019-01-07 2021-01-19 石药集团中奇制药技术(石家庄)有限公司 利伐沙班有关化合物及其制备方法和用途
CN112110910B (zh) * 2019-06-19 2024-03-19 上海特化医药科技有限公司 制备利伐沙班中间体的方法及由其制备利伐沙班的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK286569B6 (sk) 1997-11-07 2009-01-07 Pharmacia & Upjohn Company Spôsob výroby oxazolidinónov
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10300111A1 (de) 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
DE10322469A1 (de) 2003-05-19 2004-12-16 Bayer Healthcare Ag Heterocyclische Verbindungen
DE102006051625A1 (de) 2006-11-02 2008-05-08 Bayer Materialscience Ag Kombinationstherapie substituierter Oxazolidinone
DE102007028320A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007032347A1 (de) 2007-07-11 2009-01-15 Bayer Healthcare Ag Aminoacyl-Prodrugs
DE102007032345A1 (de) * 2007-07-11 2009-01-15 Bayer Healthcare Ag Aminoacyl-Prodrugs
EP2354128A1 (en) 2010-02-10 2011-08-10 Sandoz Ag Method for the preparation of rivaroxaban
CN102584738B (zh) 2011-01-07 2015-04-29 浙江九洲药业股份有限公司 一种合成利伐沙班中间体的工艺
WO2013046211A1 (en) * 2011-09-27 2013-04-04 Symed Labs Limited Processes for the preparation of 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl) phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophene-carboxamide and intermediates thereof

Also Published As

Publication number Publication date
EP2838897A1 (en) 2015-02-25
IN2014DN09450A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-07-17
SG11201406623PA (en) 2014-11-27
US20150299160A1 (en) 2015-10-22
WO2013156936A1 (en) 2013-10-24

Similar Documents

Publication Publication Date Title
AU2013250801A1 (en) Process for the preparation of rivaroxaban and intermediates thereof
CA2553237C (en) Production method
CN102753537B (zh) 制备利伐沙班的方法
CA2512504C (en) Method for producing 5-chloro-n-({5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide
AU2004272255B2 (en) Method for the production of 4-(4-aminophenyl)-3-morpholinon
US9126990B2 (en) Method for synthesizing rivaroxaban intermediate, 4-(4-[(5S)-(aminomethyl)-2-oxo-1,3-oxazoligdin-3-YL]phenyl)morpholin-3-one
CN114478690B (zh) 一种6,6-二甲基-3-氮杂双环[3.1.0]己烷衍生物的制备方法
WO2013175431A1 (en) Process for the preparation of rivaroxaban
US9663505B2 (en) Process for the preparation of rivaroxaban
CN104817550B (zh) 一种利伐沙班的制备方法
WO2015011617A1 (en) Process for the preparation of rivaroxaban
JP2023502123A (ja) S1p1モジュレーター化合物及び化合物を調製する方法
CN103265482A (zh) 博舒替尼的制备方法
CN104109158A (zh) 一种纯化利伐沙班的方法
CN104098558A (zh) 酰胺类化合物及其制备方法
US8940890B2 (en) Preparation method of 5-[[2(R)-[1(R)-[3,5-bis(trifluoromethyl) phenyl]ethoxy]-3(S)-4-fluorophenyl-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazole-3-one
CN104926807B (zh) 一种利伐沙班相关物质“二胺”及其合成方法
EP2895176B1 (en) Rivaroxaban intermediate and preparation thereof
CN104961736A (zh) 一种利伐沙班相关物质“三胺”及其合成方法
CN113943281B (zh) 异恶唑嘧啶衍生物的合成方法及其应用
CN113248420B (zh) 一种2-酰基-3-酯基吲哚类衍生物的制备方法
CN102321042B (zh) 3-取代苯基-5-羟甲基噁唑烷-2-酮的制备方法
CN116375703A (zh) 一种阿哌沙班的合成工艺
CA3228653A1 (en) Small molecule urea derivatives as sting antagonists
CN118176191A (zh) 一种利伐沙班的合成方法

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted